

Special Issue

Advances in the Treatment of Kidney and Upper Urinary Tract Cancers

Message from the Guest Editors

Kidney and Upper Tract Urinary Cancers (UTUC) are diseases of increasing population coverage, the treatment of which are undergoing a continuous process of evolution. A characteristic feature of the picture composing the results of renal cell cancer (RCC) treatment is the significant heterogeneity of patients (including different stages of local advancement, different locations of metastases). Importantly, it is estimated that up to 30% of newly diagnosed RCC cases are patients with disseminated disease at the time of diagnosis. Therefore, predicting the response to modern treatment remains the unmet need of modern urologic oncology. Recent advancements in systematic treatment, i.e., immunotherapy, shed additional light on adjuvant treatment to be implemented in new clinical scenarios, including localized disease. This Special Issue aims to cover novel approaches in the renal and urothelial cancers. We opt for original papers and reviews relating to advances in the treatment of Kidney and Upper Tract Urinary Cancers.

Guest Editors

Dr. Łukasz Zapala

Clinic of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland

Dr. Paweł Rajwa

Department of Urology, Medical University of Silesia, Zabrze, Poland

Deadline for manuscript submissions

closed (31 December 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/117426

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).